CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target

CagriSema Efficacy:
CagriSema, a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved a statistically significant and superior weight loss of 22.7% after 68 weeks compared to placebo in adults with obesity or overweight123.

Comparison to Individual Components:
The weight loss with CagriSema was superior to the individual components, with cagrilintide 2.4 mg achieving 11.8% weight loss and semaglutide 2.4 mg achieving 16.1% weight loss123.

Dosing and Adherence:
Only 57.3% of patients treated with CagriSema reached the highest dose, compared to 82.5% for cagrilintide 2.4 mg and 70.2% for semaglutide 2.4 mg123.

Safety Profile:
CagriSema appeared to be safe and well-tolerated, with most common adverse events being gastrointestinal-related and mild to moderate123.

Market Comparison:
The weight loss achieved by CagriSema is comparable to but does not exceed that of Eli Lilly and Company's tirzepatide (Zepbound), which led to an average weight loss of ~23% in clinical trials124.

Future Plans:
Novo Nordisk plans to further explore the additional weight loss potential of CagriSema, with results from the second Phase 3 trial, REDEFINE 2, in adults with type 2 diabetes and obesity or overweight anticipated for the first half of next year123.

Sources:

1. https://www.hcplive.com/view/cagrisema-achieves-22-7-weight-loss-in-phase-3-redefine-1-trial

2. https://www.patientcareonline.com/view/cagrisema-leads-to-weight-reduction-of-approximately-23-in-phase-3-redefine-1-clinical-trial-short-of-the-25-expected

3. https://www.globenewswire.com/news-release/2024/12/20/3000444/0/en/Novo-Nordisk-A-S-CagriSema-demonstrates-superior-weight-loss-in-adults-with-obesity-or-overweight-in-the-REDEFINE-1-trial.html

4. https://www.consultantlive.com/view/cagrisema-achieves-22-7-weight-loss-in-phase-3-redefine-1-trial